Drug Trial Radar · NCT00307437
A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis
Last checked: Nov 20, 2026Latest source record: Jan 24, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,230
Actual
Start
May 2005
Primary completion
Dec 2006
Study completion Oct 2011
Sponsor
- Lead sponsor
- Centocor Research & Development, Inc.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Mar 28, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy and safety of ustekinumab (CNTO 1275) in the treatment of patients with moderate to severe plaque psoriasis.
Conditions
- Psoriasis
Interventions
Placebo; Ustekinumab (CNTO 1275) 45 or 90 mgDrug
Placebo at Weeks 0 and 4 and blinded SC injections of ustekinumab, 45 or 90 mg, at Weeks 12 and 16; followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
Ustekinumab (CNTO 1275) 45 mgDrug
Ustekinumab, 45 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
Ustekinumab (CNTO 1275) 90 mgDrug
Ustekinumab, 90 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Psoriasis Area and Severity Index (PASI) Score of 75 Percent or Above at Week 12Time frame: Week 0 to Week 12
Locations
62 sites in 7 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Little Rock, Arkansas
Site not named
La Jolla, California
Site not named
Los Angeles, California
Site not named
San Diego, California
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
Normal, Illinois
Site not named
Skokie, Illinois
Site not named
Indianapolis, Indiana
Site not named
Louisville, Kentucky
Site not named
Andover, Massachusetts
Site not named
Boston, Massachusetts
Site not named
Port Huron, Michigan
Site not named
St Louis, Missouri
Site not named
Las Vegas, Nevada
Site not named
New Brunswick, New Jersey
Site not named
New York, New York
Site not named
Winston-Salem, North Carolina
Site not named
Cleveland, Ohio
Site not named
Portland, Oregon
Site not named
Philadelphia, Pennsylvania
Site not named
Plymouth Meeting, Pennsylvania
Site not named
Mt. Pleasant, South Carolina
Site not named
Nashville, Tennessee
Site not named
Houston, Texas
Site not named
San Antonio, Texas
Site not named
Salt Lake City, Utah
Site not named
Graz, Austria
Site not named
Innsbruck, Austria
Site not named
Vienna, Austria
Site not named
Calgary, Alberta, Canada
Site not named
Edmonton, Alberta, Canada
Site not named
Surrey, British Columbia, Canada
Site not named
Vancouver, British Columbia, Canada
Site not named
Moncton, New Brunswick, Canada
Site not named
Halifax, Nova Scotia, Canada
Site not named
Barrie, Ontario, Canada
Site not named
Hamilton, Ontario, Canada
Site not named
London, Ontario, Canada
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.